SLC5A2 and heart failure: Among the SGLT-2 inhibitors investigated in HFrEF, dapagliflozin has been subjected to extensive research, and it has been shown to reduce the risk of heart failure hospitalization and cardiovascular death in patients with HFrEF [11].